Of course, with these shifts comes associated regulatory implications. The FDA and EMA have been introducing best practices and guidance around using the latest technology — and will continue to do so in the coming months.
Digital transformation is no longer optional in the life sciences sector, and agility is key to your organization’s ability to capitalize on the latest shifts and remain competitive.
Join us for a deep-dive discussion between Gilad Langer, Industry Practice Lead at Tulip, and Michelle Vuolo, Quality Practice Lead at Tulip, on the current state of frontline operations — and what to expect in 2024.
In this webinar, they’ll:
Assess the predictions we had made for 2023 — and whether or not they came to fruition
Outline some of the current life sciences industry shifts and frontline operations challenges
Highlight our predictions for 2024 — providing tips on how you should adapt your strategy accordingly
Head of Quality, Tulip
Industry Practice Lead, Tulip